{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:14:44Z","timestamp":1761178484526,"version":"build-2065373602"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.canrad.2018.07.007","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T19:27:23Z","timestamp":1533065243000},"page":"404-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Technique de radioth\u00e9rapie du lymphome de Hodgkin\u00a0: points sur la radioth\u00e9rapie conformationnelle avec modulation d\u2019intensit\u00e9, le gating, la protonth\u00e9rapie. Y a-t-il des techniques \u00e0 favoriser\u00a0?"],"prefix":"10.1016","volume":"22","author":[{"given":"A.","family":"Boros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9.","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chargari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Izar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2018.07.007_bib0295","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2018.07.007_bib0300","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1756-5391.2011.01134.x","article-title":"Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma","volume":"4","author":"Skoetz","year":"2011","journal-title":"J Evid Based Med"},{"key":"10.1016\/j.canrad.2018.07.007_bib0305","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11\u00a0trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0310","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.68.6394","article-title":"response-adapted treatment in stage I and II hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10\u00a0trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0315","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu181","article-title":"Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Eichenauer","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0320","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15\u00a0trial): a randomised, open-label, phase 3\u00a0non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2018.07.007_bib0325","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.6004\/jnccn.2011.0086","article-title":"Hodgkin lymphoma: clinical practice guidelines in oncology","volume":"9","author":"Hoppe","year":"2011","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.canrad.2018.07.007_bib0330","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0335","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.005","article-title":"ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors\u00a0: results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d\u2019\u00e9tude des lymphomes de l\u2019adulte (GELA) H9-U interg","volume":"81","author":"Ferm\u00e9","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2018.07.007_bib0340","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European organisation for research and treatment of cancer H7\u00a0randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0345","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/annonc\/13.S1.79","article-title":"The involved field is back: issues in delineating the radiation field in Hodgkin's disease","volume":"13","author":"Yahalom","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0350","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2012.08.041","article-title":"Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma","volume":"85","author":"Maraldo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0355","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting Radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10\u00a0trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0360","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2018.07.007_bib0365","doi-asserted-by":"crossref","first-page":"6505a","DOI":"10.1200\/jco.2005.23.16_suppl.6505","article-title":"Final results of the EORTC-GELA H9\u00a0randomized trials: the H9-F trial (comparing 3\u00a0radiation dose levels) and H9-U trial (comparing 3\u00a0chemotherapy schemes) in patients with favourable or unfavourable early stage Hodgkin's lymphoma","volume":"23","author":"Nordijk","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0370","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00066-014-0719-9","article-title":"Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma","volume":"190","author":"Lohr","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0375","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40\u00a0years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2018.07.007_bib0380","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin's disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0385","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.canrad.2016.07.030","article-title":"Pr\u00e9vention des cancers radio-induits","volume":"20","author":"Cosset","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.07.007_bib0390","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1667\/RR0527.1","article-title":"Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects","volume":"167","author":"Suit","year":"2007","journal-title":"Radiat Res"},{"key":"10.1016\/j.canrad.2018.07.007_bib0395","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","article-title":"Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25\u00a0years","volume":"20","author":"Dores","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0400","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0405","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/jnci\/dji290","article-title":"Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma","volume":"97","author":"Travis","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2018.07.007_bib0410","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/jnci\/dji310","article-title":"Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory?","volume":"97","author":"Longo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2018.07.007_bib0415","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1684\/bdc.2013.1855","article-title":"Le probl\u00e8me des faibles doses en radioth\u00e9rapie\u00a0: quel risque de carcinogen\u00e8se radio-induite\u00a0?","volume":"100","author":"Chargari","year":"2013","journal-title":"Bull Cancer"},{"key":"10.1016\/j.canrad.2018.07.007_bib0420","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease","volume":"94","author":"Travis","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2018.07.007_bib0425","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"Van Nimwegen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2018.07.007_bib0430","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.canrad.2018.07.007_bib0435","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"Van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2018.07.007_bib0445","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2016.66.7840","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of hodgkin lymphoma","volume":"34","author":"Mazzola","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0450","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijrobp.2011.05.078","article-title":"Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy","volume":"83","author":"Fox","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0455","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijrobp.2009.07.1709","article-title":"Incidence and correlates of radiation pneumonitis in pediatric patients with partial lung irradiation","volume":"78","author":"Hua","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0460","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ijrobp.2014.04.029","article-title":"Involved-node proton therapy in combined modality therapy for hodgkin lymphoma: results of a phase 2\u00a0study","volume":"89","author":"Hoppe","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0465","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1088\/0031-9155\/59\/12\/2883","article-title":"The risk of radiation-induced second cancers in the high to medium dose region: a comparison between passive and scanned proton therapy. IMRT and VMAT for pediatric patients with brain tumors","volume":"59","author":"Moteabbed","year":"2014","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0470","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00066-015-0839-x","article-title":"Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: comparison of ILROG IS-RT and the GHSG IF-RT","volume":"191","author":"Kriz","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0475","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/0284186X.2014.932435","article-title":"Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold","volume":"54","author":"Petersen","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0480","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma","volume":"82","author":"Paumier","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0485","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.prro.2013.07.015","article-title":"Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: impact on normal tissue dose","volume":"4","author":"Charpentier","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0490","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijrobp.2005.06.004","article-title":"Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constra","volume":"64","author":"Girinsky","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0495","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijrobp.2010.09.007","article-title":"Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma","volume":"80","author":"Paumier","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0500","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijrobp.2004.08.048","article-title":"Intensity-modulated radiotherapy for lymphoma involving the mediastinum","volume":"62","author":"Goodman","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0505","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2014.01.041","article-title":"Involved-site image-guided intensity modulated versus 3d conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma","volume":"89","author":"Filippi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0510","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijrobp.2011.05.054","article-title":"Radiotherapy for early mediastinal hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy","volume":"83","author":"Koeck","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0515","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1748-717X-7-186","article-title":"Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin's lymphoma: dosimetric comparison and clinical considerations","volume":"7","author":"Fiandra","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0520","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.radonc.2006.10.015","article-title":"Comparison of three different mediastinal radiotherapy techniques in female patients: impact on heart sparing and dose to the breasts","volume":"82","author":"Nieder","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0525","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ijrobp.2009.05.012","article-title":"Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study","volume":"75","author":"Weber","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0530","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2011.12.034","article-title":"Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma","volume":"84","author":"Hoppe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0535","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canrad.2015.11.002","article-title":"Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy","volume":"20","author":"Horn","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.07.007_bib0540","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ijrobp.2008.12.048","article-title":"Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy","volume":"75","author":"Chera","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0545","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijrobp.2010.05.007","article-title":"Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma","volume":"81","author":"Li","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0550","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijrobp.2011.06.1959","article-title":"Consolidative involved-node proton therapy for stage IA-IIIB mediastinal hodgkin lymphoma: preliminary dosimetric outcomes from a phase II study","volume":"83","author":"Hoppe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0555","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","article-title":"Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma","volume":"24","author":"Maraldo","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0560","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1748-717X-8-22","article-title":"Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms","volume":"8","author":"Cella","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0565","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1120\/jacmp.v16i5.5386","article-title":"Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential","volume":"16","author":"Toltz","year":"2015","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0570","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1080\/0284186X.2016.1191665","article-title":"Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment","volume":"55","author":"Zeng","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2018.07.007_bib0575","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijrobp.2010.02.004","article-title":"Radiation therapy and late mortality from second sarcoma, carcinoma, and hematological malignancies after a solid cancer in childhood","volume":"80","author":"Tukenova","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.007_bib0290","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/annonc\/mdx287","article-title":"Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma","volume":"28","author":"Hoppe","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818301331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818301331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:28:10Z","timestamp":1761136090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321818301331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1278321818301331"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2018.07.007","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Technique de radioth\u00e9rapie du lymphome de Hodgkin\u00a0: points sur la radioth\u00e9rapie conformationnelle avec modulation d\u2019intensit\u00e9, le gating, la protonth\u00e9rapie. Y a-t-il des techniques \u00e0 favoriser\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2018.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}